CliffBio
small molecule

ICATIBANT ACETATE

ICATIBANT ACETATE

Loss of exclusivity—loss of exclusivity
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand nameICATIBANT ACETATE
Active ingredientICATIBANT ACETATE
StrengthEQ 30MG BASE/3ML (EQ 10MG BASE/ML)
Dosage formINJECTABLE
RouteSUBCUTANEOUS
ModalitySmall molecule
FDA approvalJuly 2020
Marketing statusRX

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

ICATIBANT ACETATE patent cliff — loss of exclusivity — | CliffBio